UPLOAD Filing
Acurx Pharmaceuticals, Inc.
Date: July 21, 2025 · CIK: 0001736243 · Accession: 0000000000-25-007662
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-288667
Letter
Re: Acurx Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed July 15, 2025 File No. 333-288667 Dear David Luci:
July 21, 2025
David Luci President and Chief Executive Officer Acurx Pharmaceuticals, Inc. 259 Liberty Avenue Staten Island, NY 10305
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Jeffrey D. Cohan
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> July 21, 2025 David Luci President and Chief Executive Officer Acurx Pharmaceuticals, Inc. 259 Liberty Avenue Staten Island, NY 10305 Re: Acurx Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed July 15, 2025 File No. 333-288667 Dear David Luci: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jeffrey D. Cohan </TEXT> </DOCUMENT>